Selected research
Industry Research
Vector-Based RNAi Industry Research Report 2026
Market perspective
The global Vector-Based RNAi market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Vector-Based RNAi is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Vector-Based RNAi is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Vector-Based RNAi is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Vector-Based RNAi include Alnylam Pharmaceuticals, Arcturus Therapeutics, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Ionis Pharmaceutical, Phio Pharmaceutical, Qiagen NV, Quark Pharmaceuticals and Silence Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Vector-Based RNAi market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vector-Based RNAi Market by Company
Alnylam Pharmaceuticals
Arcturus Therapeutics
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Ionis Pharmaceutical
Phio Pharmaceutical
Qiagen NV
Quark Pharmaceuticals
Silence Therapeutics
Merck & Co.
Thermo Fisher Scientific
Vector-Based RNAi Segment by Type
Custom siRNA Construction
siRNA Vectors
siRNA Design
Vector-Based RNAi Segment by Application
Hospitals
Speciality Clinics
Vector-Based RNAi Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vector-Based RNAi market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vector-Based RNAi and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vector-Based RNAi.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Vector-Based RNAi by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Vector-Based RNAi in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Custom siRNA Construction
- siRNA Vectors
- siRNA Design
Applications
- Hospitals
- Speciality Clinics
Companies covered
- Alnylam Pharmaceuticals
- Arcturus Therapeutics
- Arrowhead Pharmaceuticals
- Dicerna Pharmaceuticals
- Ionis Pharmaceutical
- Phio Pharmaceutical
- Qiagen NV
- Quark Pharmaceuticals
- Silence Therapeutics
- Merck & Co.
- Thermo Fisher Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Vector-Based RNAi Market Size (2021-2032)
- 2.2.2 Global Vector-Based RNAi Sales (2021-2032)
- 2.2.3 Global Vector-Based RNAi Market Average Price (2021-2032)
- 2.3 Vector-Based RNAi by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Custom siRNA Construction
- 2.3.3 siRNA Vectors
- 2.3.4 siRNA Design
- 2.4 Vector-Based RNAi by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospitals
- 2.4.3 Speciality Clinics
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Vector-Based RNAi Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Vector-Based RNAi Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Vector-Based RNAi Revenue of Manufacturers (2021-2026)
- 3.4 Global Vector-Based RNAi Average Price by Manufacturers (2021-2026)
- 3.5 Global Vector-Based RNAi Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Vector-Based RNAi, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Vector-Based RNAi, Product Type & Application
- 3.8 Global Manufacturers of Vector-Based RNAi, Established Date
- 3.9 Global Vector-Based RNAi Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Alnylam Pharmaceuticals
- 4.1.1 Alnylam Pharmaceuticals Company Information
- 4.1.2 Alnylam Pharmaceuticals Business Overview
- 4.1.3 Alnylam Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Alnylam Pharmaceuticals Vector-Based RNAi Product Portfolio
- 4.1.5 Alnylam Pharmaceuticals Recent Developments
- 4.2 Arcturus Therapeutics
- 4.2.1 Arcturus Therapeutics Company Information
- 4.2.2 Arcturus Therapeutics Business Overview
- 4.2.3 Arcturus Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Arcturus Therapeutics Vector-Based RNAi Product Portfolio
- 4.2.5 Arcturus Therapeutics Recent Developments
- 4.3 Arrowhead Pharmaceuticals
- 4.3.1 Arrowhead Pharmaceuticals Company Information
- 4.3.2 Arrowhead Pharmaceuticals Business Overview
- 4.3.3 Arrowhead Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Arrowhead Pharmaceuticals Vector-Based RNAi Product Portfolio
- 4.3.5 Arrowhead Pharmaceuticals Recent Developments
- 4.4 Dicerna Pharmaceuticals
- 4.4.1 Dicerna Pharmaceuticals Company Information
- 4.4.2 Dicerna Pharmaceuticals Business Overview
- 4.4.3 Dicerna Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Dicerna Pharmaceuticals Vector-Based RNAi Product Portfolio
- 4.4.5 Dicerna Pharmaceuticals Recent Developments
- 4.5 Ionis Pharmaceutical
- 4.5.1 Ionis Pharmaceutical Company Information
- 4.5.2 Ionis Pharmaceutical Business Overview
- 4.5.3 Ionis Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Ionis Pharmaceutical Vector-Based RNAi Product Portfolio
- 4.5.5 Ionis Pharmaceutical Recent Developments
- 4.6 Phio Pharmaceutical
- 4.6.1 Phio Pharmaceutical Company Information
- 4.6.2 Phio Pharmaceutical Business Overview
- 4.6.3 Phio Pharmaceutical Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Phio Pharmaceutical Vector-Based RNAi Product Portfolio
- 4.6.5 Phio Pharmaceutical Recent Developments
- 4.7 Qiagen NV
- 4.7.1 Qiagen NV Company Information
- 4.7.2 Qiagen NV Business Overview
- 4.7.3 Qiagen NV Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Qiagen NV Vector-Based RNAi Product Portfolio
- 4.7.5 Qiagen NV Recent Developments
- 4.8 Quark Pharmaceuticals
- 4.8.1 Quark Pharmaceuticals Company Information
- 4.8.2 Quark Pharmaceuticals Business Overview
- 4.8.3 Quark Pharmaceuticals Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Quark Pharmaceuticals Vector-Based RNAi Product Portfolio
- 4.8.5 Quark Pharmaceuticals Recent Developments
- 4.9 Silence Therapeutics
- 4.9.1 Silence Therapeutics Company Information
- 4.9.2 Silence Therapeutics Business Overview
- 4.9.3 Silence Therapeutics Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Silence Therapeutics Vector-Based RNAi Product Portfolio
- 4.9.5 Silence Therapeutics Recent Developments
- 4.10 Merck & Co.
- 4.10.1 Merck & Co. Company Information
- 4.10.2 Merck & Co. Business Overview
- 4.10.3 Merck & Co. Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Merck & Co. Vector-Based RNAi Product Portfolio
- 4.10.5 Merck & Co. Recent Developments
- 4.11 Thermo Fisher Scientific
- 4.11.1 Thermo Fisher Scientific Company Information
- 4.11.2 Thermo Fisher Scientific Business Overview
- 4.11.3 Thermo Fisher Scientific Vector-Based RNAi Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Thermo Fisher Scientific Vector-Based RNAi Product Portfolio
- 4.11.5 Thermo Fisher Scientific Recent Developments
5 Global Vector-Based RNAi Market Scenario by Region
- 5.1 Global Vector-Based RNAi Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Vector-Based RNAi Sales by Region: 2021-2032
- 5.2.1 Global Vector-Based RNAi Sales by Region: 2021-2026
- 5.2.2 Global Vector-Based RNAi Sales by Region: 2027-2032
- 5.3 Global Vector-Based RNAi Revenue by Region: 2021-2032
- 5.3.1 Global Vector-Based RNAi Revenue by Region: 2021-2026
- 5.3.2 Global Vector-Based RNAi Revenue by Region: 2027-2032
- 5.4 North America Vector-Based RNAi Market Facts & Figures by Country
- 5.4.1 North America Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Vector-Based RNAi Sales by Country (2021-2032)
- 5.4.3 North America Vector-Based RNAi Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Vector-Based RNAi Market Facts & Figures by Country
- 5.5.1 Europe Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Vector-Based RNAi Sales by Country (2021-2032)
- 5.5.3 Europe Vector-Based RNAi Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Vector-Based RNAi Market Facts & Figures by Country
- 5.6.1 Asia Pacific Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Vector-Based RNAi Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Vector-Based RNAi Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Vector-Based RNAi Market Facts & Figures by Country
- 5.7.1 South America Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Vector-Based RNAi Sales by Country (2021-2032)
- 5.7.3 South America Vector-Based RNAi Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Vector-Based RNAi Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Vector-Based RNAi Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Vector-Based RNAi Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Vector-Based RNAi Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Vector-Based RNAi Sales by Type (2021-2032)
- 6.1.1 Global Vector-Based RNAi Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Vector-Based RNAi Sales Market Share by Type (2021-2032)
- 6.2 Global Vector-Based RNAi Revenue by Type (2021-2032)
- 6.2.1 Global Vector-Based RNAi Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Vector-Based RNAi Revenue Market Share by Type (2021-2032)
- 6.3 Global Vector-Based RNAi Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Vector-Based RNAi Sales by Application (2021-2032)
- 7.1.1 Global Vector-Based RNAi Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Vector-Based RNAi Sales Market Share by Application (2021-2032)
- 7.2 Global Vector-Based RNAi Revenue by Application (2021-2032)
- 7.2.1 Global Vector-Based RNAi Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Vector-Based RNAi Revenue Market Share by Application (2021-2032)
- 7.3 Global Vector-Based RNAi Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Vector-Based RNAi Value Chain Analysis
- 8.1.1 Vector-Based RNAi Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Vector-Based RNAi Production Mode & Process
- 8.2 Vector-Based RNAi Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Vector-Based RNAi Distributors
- 8.2.3 Vector-Based RNAi Customers
9 Global Vector-Based RNAi Analyzing Market Dynamics
- 9.1 Vector-Based RNAi Industry Trends
- 9.2 Vector-Based RNAi Industry Drivers
- 9.3 Vector-Based RNAi Industry Opportunities and Challenges
- 9.4 Vector-Based RNAi Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst